A Registered Cohort Study on Cerebellar Ataxia
Sponsor
Ning Wang, MD., PhD. (Other)
Overall Status
Recruiting
CT.gov ID
NCT04010214
Collaborator
(none)
1,500
1
485
3.1
Study Details
Study Description
Brief Summary
Cerebellar ataxia is a form of ataxia originating in the cerebellum. Cerebellar ataxia can occur as a result of many diseases and may present with symptoms of an inability to coordinate balance, gait, extremity and eye movements. To understand the clinical and genetic characteristics of cerebellar ataxia, we establish a registered cohort to follow up Chinese patients with cerebellar ataxia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
1500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Registered Cohort Study on Cerebellar Ataxia
Actual Study Start Date
:
Jul 1, 2019
Anticipated Primary Completion Date
:
Dec 1, 2039
Anticipated Study Completion Date
:
Dec 1, 2059
Outcome Measures
Primary Outcome Measures
- The incidence of hereditary cerebellar ataxia [Up to 20years]
Look for the causative gene in the patient with cerebellar ataxia
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Patients with cerebellar ataxia based on the diagnoses of tow neurologists
-
Relatives of patients with cerebellar ataxia
-
Unrelated healthy controls
-
Participants or legal guardian(s) willing and able to complete the informed consent process
Exclusion Criteria:
- Participants are unable to comply with trial procedures and visit schedule
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Neurology ,First Affiliated Hospital Fujian Medical University | Fuzhou | Fujian | China | 350005 |
Sponsors and Collaborators
- Ning Wang, MD., PhD.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ning Wang, MD., PhD.,
The Vice President,
First Affiliated Hospital of Fujian Medical University
ClinicalTrials.gov Identifier:
NCT04010214
Other Study ID Numbers:
- MRCTA,ECFAH of FMU[2019]195
First Posted:
Jul 8, 2019
Last Update Posted:
Jan 11, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: